EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Prognostic Factors Predicting Remission Following Rituximab Therapy for Pemphigus Vulgaris

Tal Raviv, Keren Pevzner, Aviv Barzilai, Felix Pavlotsky, Sharon Baum

Acta Dermato-Venereologica · 2025

DOI: 10.2340/actadv.v105.27140 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Dermato-Venereologica, 2025. Verfasst von Tal Raviv und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Sheba Medical Center, Tel HaShomer, Ramat Gan, affiliated to the Faculty of Medicine, Tel Aviv University, Tel Aviv, Israe…. Hauptthemen laut MEDLINE: Pemphigus, Rituximab, Remission Induction, Recurrence. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pemphigus vulgaris is a chronic autoimmune blistering disease with significant morbidity. Rituximab, approved as its first-line treatment, effectively induces remission. However, few studies have analysed the prognostic factors for improved rituximab outcomes. Therefore, this study aimed to identify such factors in a cohort of pemphigus vulgaris patients. A total of 142 pemphigus vulgaris patients treated with rituximab at Sheba Medical Center, with data encompassing demographics, comorbidities, disease characteristics, and treatment outcomes, were retrospectively examined. Results showed that 61.9% of patients previously treated with mycophenolate mofetil achieved partial remission, whereas only 34.7% achieved complete remission. Patients with diabetes mellitus exhibited a significantly shorter median time to relapse compared with those without. Patients with a disease duration ≤ 16 months before rituximab therapy exhibited a shorter median time to relapse. Moreover, previous dapsone treatment extended time to relapse. Notably, sex, age at symptom onset and rituximab therapy, ethnicity, comorbidities, skin involvement, weight, rituximab dosing protocol, and other variables were not statistically significant between the complete remission and partial remission groups. These findings highlight the influence of specific patient characteristics and treatment histories on response to rituximab and time to relapse in pemphigus vulgaris patients. Understanding these factors can aid clinicians in predicting treatment outcomes and selecting the appropriate patient population for rituximab therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PemphigusRituximabRemission InductionRecurrenceHumansFemaleMaleRetrospective StudiesMiddle AgedTreatment OutcomeAdultAgedTime FactorsMycophenolic AcidRisk FactorsImmunosuppressive AgentsImmunologic Factors

Substanzen

RituximabMycophenolic AcidImmunosuppressive AgentsImmunologic Factors

Autor:innen und Institutionen

  • Department of Dermatology, Sheba Medical Center, Tel HaShomer, Ramat Gan, affiliated to the Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. tal.raviv7@gmail.com.
  • Department of Dermatology, Sheba Medical Center, Tel HaShomer, Ramat Gan, affiliated to the Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Department of Dermatology, Sheba Medical Center, Tel HaShomer, Ramat Gan, affiliated to the Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Institute of Pathology, Sheba Medical Center, Tel HaShomer, Ramat G…
  • Department of Dermatology, Sheba Medical Center, Tel HaShomer, Ramat Gan, affiliated to the Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Phototherapy Unit, Department of Dermatology, Sheba Medical Center,…

Zitieren

APA

Raviv, T., Pevzner, K., Barzilai, A., Pavlotsky, F., & Baum, S. (2025). Prognostic Factors Predicting Remission Following Rituximab Therapy for Pemphigus Vulgaris. Acta Dermato-Venereologica. https://doi.org/10.2340/actadv.v105.27140

Vancouver

Raviv T, Pevzner K, Barzilai A, Pavlotsky F, Baum S. Prognostic Factors Predicting Remission Following Rituximab Therapy for Pemphigus Vulgaris. Acta Dermato-Venereologica. 2025. doi:10.2340/actadv.v105.27140

BibTeX
@article{Raviv2025,
  author = {Raviv, Tal and Pevzner, Keren and Barzilai, Aviv and Pavlotsky, Felix and Baum, Sharon},
  title = {Prognostic Factors Predicting Remission Following Rituximab Therapy for Pemphigus Vulgaris},
  journal = {Acta Dermato-Venereologica},
  year = {2025},
  doi = {10.2340/actadv.v105.27140}
}
Kostenlos starten →